RxDoctor Payments Data

Steven West, MD

Cardiovascular Disease · Seymour, INNPI 1356346696

Payments from drug & device makers

$321in general payments, 2019–2025

Across 14 payments — averaging $22.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intersect ENT, Inc.$115
  • E.r. Squibb & Sons, L.L.C.$63
  • Pfizer$41
  • Novartis$35
  • Boston Scientific$24
  • Amgen$15
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$27686%
  • Education$4514%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$321 in reported general payments places this provider in the 15th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$146,778
Medicare patients
493
Services billed
1,714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban588$628,240
EntrestoSacubitril/Valsartan304$348,560
XareltoRivaroxaban119$122,678
JardianceEmpagliflozin86$110,370
Ranolazine ErRanolazine190$20,150
CorlanorIvabradine Hcl21$12,038
Metoprolol Succinate774$7,995
Spironolactone313$2,500
Atorvastatin Calcium335$2,157
Amiodarone Hcl148$1,948
Carvedilol341$1,892
Torsemide79$1,837
Isosorbide Mononitrate ErIsosorbide Mononitrate187$1,789
Diltiazem 24hr Er (Cd)Diltiazem Hcl72$1,737
Valsartan73$1,730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$41$628,240588 claims
NovartisEntresto$35$348,560304 claims
Johnson & JohnsonXarelto$14$122,678119 claims
AmgenCorlanor$15$12,03821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Seymour

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →